Cellbyte, a Munich-based AI-native platform helping pharmaceutical companies accelerate drug launches, has raised $2.75 ...

GSK and the Fleming Initiative have announced six new research programmes to combat antimicrobial resistance (AMR), backed by ...

Scottish Brain Sciences (SBS) has opened a new clinical research centre at ONE BioHub in Aberdeen, marking a significant step forward in early Alzheimer’s research and trial accessibility across ...

Biogen has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has ...

Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab ...

Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s ...

Adocia has announced the filing of a patent for its new long-acting peptide platform, AdoXLong, aimed at improving treatment options for diabetes and obesity. The French biopharmaceutical company said ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...